<!DOCTYPE html>
<html class="client-js"><head>
  <meta charset=UTF-8"UTF-8">
  <title>Bivalirudin</title>
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <script>
    function importScript() { return 1 } // this is to avoid the error from site.js
  </script>
  <link rel="canonical" href="https://en.wikipedia.org/wiki/Bivalirudin">
  <link href="../-/s/css_modules/ext.cite.ux-enhancements.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/ext.cite.ux-enhancements.css" rel="stylesheet" type="text/css" class="">
<link href="../-/s/css_modules/ext.cite.styles.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/ext.cite.styles.css" rel="stylesheet" type="text/css" class="">
<link href="../-/s/css_modules/fi000001.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/skins.minerva.base.reset|skins.minerva.content.styles|ext.cite.style|site.styles|mobile.app.pagestyles.android|mediawiki.page.gallery.styles|mediawiki.skinning.content.parsoid.css" rel="stylesheet" type="text/css" class="">
  <link href="../-/s/css_modules/style.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/style.css" rel="stylesheet" type="text/css" class=""><link href="../-/s/css_modules/content.parsoid.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/content.parsoid.css" rel="stylesheet" type="text/css" class=""><link href="../-/s/css_modules/inserted_style.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/inserted_style.css" rel="stylesheet" type="text/css" class="">
  <script src="../-/j/js_modules/script.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/script.js" class=""></script><script src="../-/j/js_modules/masonry.min.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/masonry.min.js" class=""></script><script src="../-/j/js_modules/article_list_home.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/article_list_home.js" class=""></script><script src="../-/j/js_modules/images_loaded.min.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/images_loaded.min.js" class=""></script><script src="../-/j/js_modules/node_module/details-element-polyfill/dist/details-element-polyfill.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/node_module/details-element-polyfill/dist/details-element-polyfill.js" class=""></script>
<link type="root" href=""></head>

<body class="mediawiki mw-hide-empty-elt ns-0 ns-subject stable skin-minerva action-view animations">
  <div id="mw-mf-viewport" class="feature-header-v2">
    <div id="mw-mf-page-center">
      <div id="content" class="mw-body">
        <a id="top"></a>
        <div id="bodyContent" class="content mw-parser-output">
          
          <div id="mw-content-text" style="direction: ltr;"><h1 class="section-heading" tabindex="0" aria-haspopup="true" data-section-id="0">
  <span class="mw-headline" id="title_0">Bivalirudin</span>
</h1>
<div id="mf-section-0" class="mf-section-0" aria-pressed="true" aria-expanded="true">
  <p><b>Bivalirudin</b> (Angiomax or Angiox, manufactured by The Medicines Company) is a direct thrombin inhibitor (DTI).<span class="mw-ref" id="cite_ref-Angiomax_1-0"><a href="#cite_note-Angiomax-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span></p>

<table class="infobox" style="width:22em;border-spacing:2px;"><caption><span>Bivalirudin</span></caption><tbody><tr><td colspan="2" style="text-align:center"><figure-inline class="mw-default-size"><img src="../I/m/Bivalirudin.png" tppabs="https://ptable.com/wiki/compounds/I/m/Bivalirudin.png" data-file-width="3132" data-file-height="1211" data-file-type="bitmap" height="85" width="220"></figure-inline></td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Clinical data</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Trade names</th><td>Angiomax</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Other names</th><td>d-Phenylalanyl-l-prolyl-l-arginyl<br>-l-prolylglycylglycylglycylglycyl-l-asparaginylglycyl<br>-l-alpha-aspartyl-l-phenylalanyl<br>-l-alpha-glutamyl-l-alpha-glutamyl-l-isoleucyl<br>-l-prolyl-l-alpha-glutamyl-l-alpha-glutamyl<br>-l-tyrosyl-l-leucine</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">AHFS/Drugs.com</th><td><span><a href="javascript:if(confirm('https://www.drugs.com/monograph/bivalirudin.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugs.com/monograph/bivalirudin.html'" tppabs="https://www.drugs.com/monograph/bivalirudin.html" class="external text external">Monograph</a></span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">License data</th><td><div class="plainlist">
<ul><li><small><abbr class="country-name">EU</abbr></small><span>&nbsp;</span>EMA:<span>&nbsp;</span><span><a href="javascript:if(confirm('http://www.ema.europa.eu/ema/index.jsp?curl=%2Fpages%2Fmedicines%2Flanding%2Fepar_search.jsp&mid=&searchTab=searchByKey&alreadyLoaded=true&isNewQuery=true&status=Authorised&status=Withdrawn&status=Suspended&status=Refused&keywordSearch=Submit&searchType=inn&taxonomyPath=&treeNumber=&searchGenericType=generics&keyword=Bivalirudin  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.ema.europa.eu/ema/index.jsp?curl=%2Fpages%2Fmedicines%2Flanding%2Fepar_search.jsp&mid=&searchTab=searchByKey&alreadyLoaded=true&isNewQuery=true&status=Authorised&status=Withdrawn&status=Suspended&status=Refused&keywordSearch=Submit&searchType=inn&taxonomyPath=&treeNumber=&searchGenericType=generics&keyword=Bivalirudin'" tppabs="http://www.ema.europa.eu/ema/index.jsp?curl=%2Fpages%2Fmedicines%2Flanding%2Fepar_search.jsp&mid=&searchTab=searchByKey&alreadyLoaded=true&isNewQuery=true&status=Authorised&status=Withdrawn&status=Suspended&status=Refused&keywordSearch=Submit&searchType=inn&taxonomyPath=&treeNumber=&searchGenericType=generics&keyword=Bivalirudin" class="external text external">by INN</a></span></li></ul></div>
</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Pregnancy<br>category</th><td><div class="plainlist">
<ul><li><small><abbr class="country-name">US</abbr>:</small><span> </span>B (No risk in non-human studies)<span> </span></li></ul>

<ul></ul>
</div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Routes of<br>administration</th><td>Intravenous injection/infusion only</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ATC code</th><td><div class="plainlist"><ul><li>B01AE06<span> </span>(<span><a href="javascript:if(confirm('https://www.whocc.no/atc_ddd_index/?code=B01AE06  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.whocc.no/atc_ddd_index/?code=B01AE06'" tppabs="https://www.whocc.no/atc_ddd_index/?code=B01AE06" class="external text external">WHO</a></span>)<span> </span></li></ul></div></td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Legal status</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Legal status</th><td><div class="plainlist">
<ul><li>In<span>&nbsp;</span>general: ℞<span>&nbsp;</span>(Prescription only)</li></ul></div>
</td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Pharmacokinetic data</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Bioavailability</th><td>N/A (IV application only)</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Metabolism</th><td>Angiomax is cleared from plasma by a combination of renal mechanisms and proteolytic cleavage</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Elimination <span class="nowrap">half-life</span></th><td>~25 minutes in patients with normal renal function</td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Identifiers</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">CAS Number</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('http://www.commonchemistry.org/ChemicalDetail.aspx?ref=128270-60-0  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.commonchemistry.org/ChemicalDetail.aspx?ref=128270-60-0'" tppabs="http://www.commonchemistry.org/ChemicalDetail.aspx?ref=128270-60-0" class="external text external">128270-60-0</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">PubChem <span style="font-weight:normal"><abbr>CID</abbr></span></th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://pubchem.ncbi.nlm.nih.gov/compound/16129704  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubchem.ncbi.nlm.nih.gov/compound/16129704'" tppabs="https://pubchem.ncbi.nlm.nih.gov/compound/16129704" class="external text external">16129704</a></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">IUPHAR/BPS</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6470  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6470'" tppabs="http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6470" class="external text external">6470</a></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">DrugBank</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://www.drugbank.ca/drugs/DB00006  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugbank.ca/drugs/DB00006'" tppabs="https://www.drugbank.ca/drugs/DB00006" class="external text external">DB00006</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ChemSpider</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('http://www.chemspider.com/Chemical-Structure.10482069.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.chemspider.com/Chemical-Structure.10482069.html'" tppabs="http://www.chemspider.com/Chemical-Structure.10482069.html" class="external text external">10482069</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">UNII</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=TN9BEX005G  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=TN9BEX005G'" tppabs="https://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=TN9BEX005G" class="external text external">TN9BEX005G</a></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ChEBI</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:59173  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:59173'" tppabs="https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:59173" class="external text external">CHEBI:59173</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ChEMBL</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/ChEMBL1201455  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/ChEMBL1201455'" tppabs="https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/ChEMBL1201455" class="external text external">ChEMBL1201455</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/X_mark.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/X_mark.svg.png" data-file-width="525" data-file-height="600" data-file-type="drawing" height="8" width="7"></span></figure-inline><span style="display:none">N</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">CompTox Dashboard <span style="font-weight:normal">(<abbr>EPA</abbr>)</span></th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://comptox.epa.gov/dashboard/DTXSID00155847  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://comptox.epa.gov/dashboard/DTXSID00155847'" tppabs="https://comptox.epa.gov/dashboard/DTXSID00155847" class="external text external">DTXSID00155847</a> <figure-inline class="mw-valign-text-top"><img src="../I/m/OOjs_UI_icon_edit-ltr-progressive.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/OOjs_UI_icon_edit-ltr-progressive.svg.png" data-file-width="20" data-file-height="20" data-file-type="drawing" height="10" width="10"></figure-inline></span></li></ul></div></td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Chemical and physical data</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Formula</th><td><span>C</span><sub>98</sub><span>H</span><sub>138</sub><span>N</span><sub>24</sub><span>O</span><sub>33</sub></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Molar mass</th><td><span class="nowrap">2<span style="margin-left:.25em;">180</span>.317</span><span>&nbsp;</span>g·mol<sup>−1</sup></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">3D model (JSmol)</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://chemapps.stolaf.edu/jmol/jmol.php?model=CC%5BC%40H%5D%28C%29%5BC%40%40H%5D%28C%28%3DO%29N1CCC%5BC%40H%5D1C%28%3DO%29N%5BC%40%40H%5D%28CCC%28%3DO%29O%29C%28%3DO%29N%5BC%40%40H%5D%28CCC%28%3DO%29O%29C%28%3DO%29N%5BC%40%40H%5D%28CC2%3DCC%3DC%28C%3DC2%29O%29C%28%3DO%29N%5BC%40%40H%5D%28CC%28C%29C%29C%28%3DO%29O%29NC%28%3DO%29%5BC%40H%5D%28CCC%28%3DO%29O%29NC%28%3DO%29%5BC%40H%5D%28CCC%28%3DO%29O%29NC%28%3DO%29%5BC%40H%5D%28CC3%3DCC%3DCC%3DC3%29NC%28%3DO%29%5BC%40H%5D%28CC%28%3DO%29O%29NC%28%3DO%29CNC%28%3DO%29%5BC%40H%5D%28CC%28%3DO%29N%29NC%28%3DO%29CNC%28%3DO%29CNC%28%3DO%29CNC%28%3DO%29CNC%28%3DO%29%5BC%40%40H%5D4CCCN4C%28%3DO%29%5BC%40H%5D%28CCCNC%28%3DN%29N%29NC%28%3DO%29%5BC%40%40H%5D5CCCN5C%28%3DO%29%5BC%40%40H%5D%28CC6%3DCC%3DCC%3DC6%29N  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://chemapps.stolaf.edu/jmol/jmol.php?model=CC%5BC%40H%5D%28C%29%5BC%40%40H%5D%28C%28%3DO%29N1CCC%5BC%40H%5D1C%28%3DO%29N%5BC%40%40H%5D%28CCC%28%3DO%29O%29C%28%3DO%29N%5BC%40%40H%5D%28CCC%28%3DO%29O%29C%28%3DO%29N%5BC%40%40H%5D%28CC2%3DCC%3DC%28C%3DC2%29O%29C%28%3DO%29N%5BC%40%40H%5D%28CC%28C%29C%29C%28%3DO%29O%29NC%28%3DO%29%5BC%40H%5D%28CCC%28%3DO%29O%29NC%28%3DO%29%5BC%40H%5D%28CCC%28%3DO%29O%29NC%28%3DO%29%5BC%40H%5D%28CC3%3DCC%3DCC%3DC3%29NC%28%3DO%29%5BC%40H%5D%28CC%28%3DO%29O%29NC%28%3DO%29CNC%28%3DO%29%5BC%40H%5D%28CC%28%3DO%29N%29NC%28%3DO%29CNC%28%3DO%29CNC%28%3DO%29CNC%28%3DO%29CNC%28%3DO%29%5BC%40%40H%5D4CCCN4C%28%3DO%29%5BC%40H%5D%28CCCNC%28%3DN%29N%29NC%28%3DO%29%5BC%40%40H%5D5CCCN5C%28%3DO%29%5BC%40%40H%5D%28CC6%3DCC%3DCC%3DC6%29N'" tppabs="https://chemapps.stolaf.edu/jmol/jmol.php?model=CC%5BC%40H%5D%28C%29%5BC%40%40H%5D%28C%28%3DO%29N1CCC%5BC%40H%5D1C%28%3DO%29N%5BC%40%40H%5D%28CCC%28%3DO%29O%29C%28%3DO%29N%5BC%40%40H%5D%28CCC%28%3DO%29O%29C%28%3DO%29N%5BC%40%40H%5D%28CC2%3DCC%3DC%28C%3DC2%29O%29C%28%3DO%29N%5BC%40%40H%5D%28CC%28C%29C%29C%28%3DO%29O%29NC%28%3DO%29%5BC%40H%5D%28CCC%28%3DO%29O%29NC%28%3DO%29%5BC%40H%5D%28CCC%28%3DO%29O%29NC%28%3DO%29%5BC%40H%5D%28CC3%3DCC%3DCC%3DC3%29NC%28%3DO%29%5BC%40H%5D%28CC%28%3DO%29O%29NC%28%3DO%29CNC%28%3DO%29%5BC%40H%5D%28CC%28%3DO%29N%29NC%28%3DO%29CNC%28%3DO%29CNC%28%3DO%29CNC%28%3DO%29CNC%28%3DO%29%5BC%40%40H%5D4CCCN4C%28%3DO%29%5BC%40H%5D%28CCCNC%28%3DN%29N%29NC%28%3DO%29%5BC%40%40H%5D5CCCN5C%28%3DO%29%5BC%40%40H%5D%28CC6%3DCC%3DCC%3DC6%29N" class="external text external">Interactive image</a></span></li></ul></div></td></tr><tr><td colspan="2" style="text-align:center"><div class="NavFrame collapsed" style="border: none; padding: 0;">
<div class="NavHead" style="font-size: 105%; background: transparent; text-align: left;">SMILES</div>
<ul class="NavContent" style="list-style: none none; margin-left: 0; word-break:break-all; font-size: 105%; margin-top: 0; margin-bottom: 0; line-height: inherit;"><li style="line-height: inherit; margin: 0"><div style="word-wrap:break-word; text-indent:-1.5em; text-align:left; padding-left:1.5em; font-size:11px; line-height:120%;">CC[C@H](C)[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CC(C)C)C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)O)NC(=O)CNC(=O)[C@H](CC(=O)N)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@@H]4CCCN4C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]5CCCN5C(=O)[C@@H](CC6=CC=CC=C6)N</div></li></ul>
</div></td></tr><tr><td colspan="2" style="text-align:center"><div class="NavFrame collapsed" style="border: none; padding: 0;">
<div class="NavHead" style="font-size: 105%; background: transparent; text-align: left;">InChI</div>
<ul class="NavContent" style="list-style: none none; margin-left: 0; word-break:break-all; font-size: 105%; margin-top: 0; margin-bottom: 0; line-height: inherit;"><li style="line-height: inherit; margin: 0"><div style="word-wrap:break-word; text-indent:-1.5em; text-align:left; padding-left:1.5em; font-size:11px; line-height:120%;">InChI=1S/C98H138N24O33/c1-5-52(4)82(96(153)122-39-15-23-70(122)92(149)114-60(30-34-79(134)135)85(142)111-59(29-33-78(132)133)86(143)116-64(43-55-24-26-56(123)27-25-55)89(146)118-67(97(154)155)40-51(2)3)119-87(144)61(31-35-80(136)137)112-84(141)58(28-32-77(130)131)113-88(145)63(42-54-18-10-7-11-19-54)117-90(147)66(45-81(138)139)110-76(129)50-107-83(140)65(44-71(100)124)109-75(128)49-106-73(126)47-104-72(125)46-105-74(127)48-108-91(148)68-21-13-38-121(68)95(152)62(20-12-36-103-98(101)102)115-93(150)69-22-14-37-120(69)94(151)57(99)41-53-16-8-6-9-17-53/h6-11,16-19,24-27,51-52,57-70,82,123H,5,12-15,20-23,28-50,99H2,1-4H3,(H2,100,124)(H,104,125)(H,105,127)(H,106,126)(H,107,140)(H,108,148)(H,109,128)(H,110,129)(H,111,142)(H,112,141)(H,113,145)(H,114,149)(H,115,150)(H,116,143)(H,117,147)(H,118,146)(H,119,144)(H,130,131)(H,132,133)(H,134,135)(H,136,137)(H,138,139)(H,154,155)(H4,101,102,103)/t52-,57+,58-,59-,60-,61-,62-,63-,64-,65-,66-,67-,68-,69-,70-,82-/m0/s1<sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></div></li><li style="line-height: inherit; margin: 0"><div style="word-wrap:break-word; text-indent:-1.5em; text-align:left; padding-left:1.5em; font-size:11px; line-height:120%;">Key:OIRCOABEOLEUMC-GEJPAHFPSA-N<sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></div></li></ul>
</div></td></tr><tr><td colspan="2" style="text-align:center"><style data-mw-deduplicate="TemplateStyles:r886047488">.mw-parser-output .nobold{font-weight:normal}</style><span class="nobold"><span>&nbsp;</span><sup><figure-inline><span><img src="../I/m/X_mark.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/X_mark.svg.png" data-file-width="525" data-file-height="600" data-file-type="drawing" height="8" width="7"></span></figure-inline><span style="display:none">N</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup><span>&nbsp;</span>(what is this?)</span><span class="nobold"><span>&nbsp;</span><span>&nbsp;</span><span class="reflink  nourlexpansion"><a href="javascript:if(confirm('https://en.wikipedia.org/w/index.php?title=Special:ComparePages&rev1=459980478&page2=Bivalirudin  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://en.wikipedia.org/w/index.php?title=Special:ComparePages&rev1=459980478&page2=Bivalirudin'" tppabs="https://en.wikipedia.org/w/index.php?title=Special:ComparePages&rev1=459980478&page2=Bivalirudin" class="external text external">(verify)</a></span></span></td></tr></tbody></table>

<p>Chemically, it is a synthetic congener of the naturally occurring drug hirudin (found in the saliva of the medicinal leech <i>Hirudo medicinalis</i>).</p>

<p>Bivalirudin is a DTI that overcomes many limitations seen with indirect thrombin inhibitors, such as <a href="Heparin.htm" tppabs="https://ptable.com/wiki/compounds/A/Heparin" title="Heparin">heparin</a>. Bivalirudin is a short, synthetic peptide. It is a potent and highly specific inhibitor of <a href="Thrombin.htm" tppabs="https://ptable.com/wiki/compounds/A/Thrombin" title="Thrombin">thrombin</a>.<span class="mw-ref" id="cite_ref-Angiomax_1-1"><a href="#cite_note-Angiomax-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span><span class="mw-ref" id="cite_ref-Anand2007_2-0"><a href="#cite_note-Anand2007-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span><span class="mw-ref" id="cite_ref-Weitz1990_3-0"><a href="#cite_note-Weitz1990-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span> It inhibits both circulating and clot-bound thrombin,<span class="mw-ref" id="cite_ref-Weitz1990_3-1"><a href="#cite_note-Weitz1990-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span> while also inhibiting thrombin-mediated platelet activation and aggregation.<span class="mw-ref" id="cite_ref-Stone2006_4-0"><a href="#cite_note-Stone2006-4" style="counter-reset: mw-Ref 4;"><span class="mw-reflink-text">[4]</span></a></span> Bivalirudin has a quick onset of action and a short half-life.<span class="mw-ref" id="cite_ref-Angiomax_1-2"><a href="#cite_note-Angiomax-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span> It does not bind to plasma proteins (other than thrombin) or to red blood cells. Therefore, it has a predictable antithrombotic response. There is no risk for Heparin Induced Thrombocytopenia/Heparin Induced Thrombosis-Thrombocytopenia Syndrome (HIT/HITTS).<span class="mw-ref" id="cite_ref-Angiomax_1-3"><a href="#cite_note-Angiomax-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span> It does not require a binding cofactor such as antithrombin and does not activate platelets.<span class="mw-ref" id="cite_ref-Anand2007_2-1"><a href="#cite_note-Anand2007-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span><span class="mw-ref" id="cite_ref-Weitz2002_5-0"><a href="#cite_note-Weitz2002-5" style="counter-reset: mw-Ref 5;"><span class="mw-reflink-text">[5]</span></a></span> These characteristics make bivalirudin an ideal alternative to heparin.</p>

<p>Bivalirudin clinical studies demonstrated consistent positive outcomes in patients with stable angina, unstable angina (UA), non-ST segment elevation myocardial infarction (NSTEMI), and ST-segment elevation myocardial infarction (STEMI) undergoing PCI in 7 major randomized trials.<span class="mw-ref" id="cite_ref-Angiomax_1-4"><a href="#cite_note-Angiomax-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span><span class="mw-ref" id="cite_ref-Weitz1990_3-2"><a href="#cite_note-Weitz1990-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span><span class="mw-ref" id="cite_ref-Stone2006_4-1"><a href="#cite_note-Stone2006-4" style="counter-reset: mw-Ref 4;"><span class="mw-reflink-text">[4]</span></a></span><span class="mw-ref" id="cite_ref-Bittl2001_6-0"><a href="#cite_note-Bittl2001-6" style="counter-reset: mw-Ref 6;"><span class="mw-reflink-text">[6]</span></a></span><span class="mw-ref" id="cite_ref-Lincoff2003_7-0"><a href="#cite_note-Lincoff2003-7" style="counter-reset: mw-Ref 7;"><span class="mw-reflink-text">[7]</span></a></span> Patients receiving bivalirudin had fewer adverse events compared to patients that received heparin.<span class="mw-ref" id="cite_ref-8"><a href="#cite_note-8" style="counter-reset: mw-Ref 8;"><span class="mw-reflink-text">[8]</span></a></span><span class="mw-ref" id="cite_ref-9"><a href="#cite_note-9" style="counter-reset: mw-Ref 9;"><span class="mw-reflink-text">[9]</span></a></span></p>


</div><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Indications">Indications</h2></summary>
    


    <details data-level="3" open="">
    <summary class="section-heading"><h3 id="US_(United_States)">US (United States)</h3></summary>
    

<ul><li>Bivalirudin is indicated for use as an anticoagulant in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty (PTCA).<span class="mw-ref" id="cite_ref-Angiomax_1-5"><a href="#cite_note-Angiomax-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span></li>
<li>Bivalirudin with provisional use of glycoprotein IIb/IIIa inhibitor (GPI) is indicated for use as an anticoagulant in patients undergoing percutaneous coronary intervention (PCI).</li>
<li>Bivalirudin is indicated for patients with, or at risk of HIT/HITTS undergoing PCI.</li>
<li>Bivalirudin is intended for use with aspirin and has been studied only in patients receiving concomitant aspirin</li></ul>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="EU_(European)">EU (European)</h3></summary>
    

<ul><li>Percutaneous Coronary Intervention (PCI), including patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary PCI.<span class="mw-ref" id="cite_ref-Angiox_10-0"><a href="#cite_note-Angiox-10" style="counter-reset: mw-Ref 10;"><span class="mw-reflink-text">[10]</span></a></span></li>
<li>Bivalirudin is also indicated for the treatment of adult patients with unstable angina/non-ST segment elevation myocardial infarction (UA/NSTEMI) planned for urgent or early intervention.</li>
<li>Bivalirudin should be administered with aspirin and clopidogrel.</li></ul>


</details>

</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Basic_chemical_and_pharmacological_properties">Basic chemical and pharmacological properties</h2></summary>
    


    <details data-level="3" open="">
    <summary class="section-heading"><h3 id="Mechanism_of_action">Mechanism of action</h3></summary>
    

<p>Bivalirudin directly inhibits thrombin by specifically binding both to the catalytic site and to the anion-binding exosite of circulating and clot-bound thrombin.<span class="mw-ref" id="cite_ref-Angiomax_1-6"><a href="#cite_note-Angiomax-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span> Thrombin is a serine proteinase that plays a central role in the thrombotic process. It cleaves fibrinogen into fibrin monomers, activates Factor V, VIII, and XIII, allowing fibrin to develop a covalently cross-linked framework that stabilizes the thrombus. Thrombin also promotes further thrombin generation, and activates platelets, stimulating aggregation and granule release. The binding of bivalirudin to thrombin is reversible as thrombin slowly cleaves the bivalirudin-Arg<sub>3</sub>-Pro<sub>4</sub> bond, resulting in recovery of thrombin active site functions.<span class="mw-ref" id="cite_ref-11"><a href="#cite_note-11" style="counter-reset: mw-Ref 11;"><span class="mw-reflink-text">[11]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Pharmacokinetics">Pharmacokinetics</h3></summary>
    

<ul><li>Following an IV bolus of bivalirudin of 1<span>&nbsp;</span>mg/kg and a 4-hour 2.5<span>&nbsp;</span>mg/kg/h IV infusion a mean steady state concentration of 12.3 ± 1.7<span>&nbsp;</span>µg/mL is achieved<span class="mw-ref" id="cite_ref-Angiomax_1-7"><a href="#cite_note-Angiomax-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span></li>
<li>Bivalirudin is cleared from plasma by a combination of renal mechanisms and proteolytic cleavage</li>
<li>Half-life:</li></ul>

<p>-Normal renal function (≥<span>&nbsp;</span>90<span>&nbsp;</span>mL/min) = 25 minutes</p>

<p>-Mild renal dysfunction (60–89<span>&nbsp;</span>mL/min) = 22 minutes</p>

<p>-Moderate renal dysfunction (30-59<span>&nbsp;</span>mL/min) = 34 minutes</p>

<p>-Severe renal dysfunction (≤<span>&nbsp;</span>29<span>&nbsp;</span>mL/min) = 57 minutes</p>

<p>-Dialysis-dependent  = 3.5 hours</p>

<ul><li>Clearance is reduced approximately 20% in patients with moderate and severe renal impairment and by 80% in dialysis-dependent patients</li>
<li>Bivalirudin is hemodialyzable and approximately 25% is cleared by hemodialysis.</li></ul>

<p><b>Pharmacodynamics</b><span class="mw-ref" id="cite_ref-Angiomax_1-8"><a href="#cite_note-Angiomax-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span></p>

<p>Coagulation times return to baseline approximately 1 hour following cessation of bivalirudin administration.</p>


</details>

</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Dosing_and_administration">Dosing and administration</h2></summary>
    

<p>Bivalirudin is intended for IV use only and is supplied as a sterile, lyophilized product in single-use, glass vials. After reconstitution, each vial delivers 250<span>&nbsp;</span>mg of bivalirudin.</p>

<p><i><b>US dosing</b></i>:<span class="mw-ref" id="cite_ref-Angiomax_1-9"><a href="#cite_note-Angiomax-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span></p>

<ul><li>PCI Bolus: 0.75<span>&nbsp;</span>mg/kg</li>
<li>PCI Infusion: 1.75<span>&nbsp;</span>mg/kg/h</li></ul>

<p><i><b>EU dosing</b></i>:<span class="mw-ref" id="cite_ref-Angiox_10-1"><a href="#cite_note-Angiox-10" style="counter-reset: mw-Ref 10;"><span class="mw-reflink-text">[10]</span></a></span></p>

<ul><li>UA/NSTEMI</li></ul>

<p>-Bolus: 0.1<span>&nbsp;</span>mg/kg</p>

<p>-Infusion: 0.25<span>&nbsp;</span>mg/kg/h for up to 72 hours for medical management</p>

<p>-If patient proceeds to PCI, an additional bolus of 0.5<span>&nbsp;</span>mg/kg of bivalirudin should be administered before the procedure and the infusion increased to 1.75<span>&nbsp;</span>mg/kg/h for the duration of the procedure.</p>

<ul><li>PCI</li></ul>

<p>-Bolus: 0.75<span>&nbsp;</span>mg/kg</p>

<p>-Infusion: 1.75<span>&nbsp;</span>mg/kg/h</p>

<ul><li>Coronary Artery Bypass Graft (CABG)</li></ul>

<p>-Patients proceeding to CABG surgery off-pump:</p>

<p>The IV infusion of bivalirudin should be continued until the time of surgery. Just prior to surgery, a 0.5<span>&nbsp;</span>mg/kg bolus dose should be administered followed by a 1.75<span>&nbsp;</span>mg/kg/h infusion for the duration of the surgery.</p>

<p>-Patients proceeding to CABG surgery on-pump:</p>

<p>The IV infusion of bivalirudin should be continued until 1 hour prior to surgery after which the infusion should be discontinued</p>

<p>Five minutes after the bolus dose has been administered, an activating clotting time (ACT) should be performed and an additional bolus of 0.3<span>&nbsp;</span>mg/kg should be given if needed.<span class="mw-ref" id="cite_ref-Angiomax_1-10"><a href="#cite_note-Angiomax-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span></p>

<p>Continuation of the bivalirudin infusion following PCI for up to 4 hours post-procedure is optional, at the discretion of the treating physician. After 4 hours, an additional IV infusion of bivalirudin may be initiated at a rate of 0.2 or 0.25<span>&nbsp;</span>mg/kg/h for up to 20 hours, if needed.<span class="mw-ref" id="cite_ref-Angiomax_1-11"><a href="#cite_note-Angiomax-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span><span class="mw-ref" id="cite_ref-Angiox_10-2"><a href="#cite_note-Angiox-10" style="counter-reset: mw-Ref 10;"><span class="mw-reflink-text">[10]</span></a></span></p>

<p>Bivalirudin should be administered with optimal antiplatelet therapy (aspirin plus clopidogrel).<span class="mw-ref" id="cite_ref-Angiomax_1-12"><a href="#cite_note-Angiomax-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span><span class="mw-ref" id="cite_ref-Angiox_10-3"><a href="#cite_note-Angiox-10" style="counter-reset: mw-Ref 10;"><span class="mw-reflink-text">[10]</span></a></span></p>

<p><i><b>Renal impairment</b></i></p>

<p>A reduction in the infusion dose of bivalirudin should be considered in patients with moderate or severe renal impairment. If a patient is on hemodialysis, the infusion should be reduced to 0.25<span>&nbsp;</span>mg/kg/h. No reduction in the bolus dose is needed.<span class="mw-ref" id="cite_ref-Angiomax_1-13"><a href="#cite_note-Angiomax-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span><span class="mw-ref" id="cite_ref-Angiox_10-4"><a href="#cite_note-Angiox-10" style="counter-reset: mw-Ref 10;"><span class="mw-reflink-text">[10]</span></a></span></p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Safety_information">Safety information</h2></summary>
    

<p>Bivalirudin is contraindicated in patients with active major bleeding and hypersensitivity to bivalirudin or its components. (In the EU bivalirudin is also contraindicated in patients with an increased risk of bleeding due to hemostasis disorders and/or irreversible coagulation disorders, severe uncontrolled hypertension, subacute bacterial endocarditis, and severe renal impairment [GFR&lt;30 ml/min] and in dialysis-dependent patients).<span class="mw-ref" id="cite_ref-Angiomax_1-14"><a href="#cite_note-Angiomax-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span><span class="mw-ref" id="cite_ref-Angiox_10-5"><a href="#cite_note-Angiox-10" style="counter-reset: mw-Ref 10;"><span class="mw-reflink-text">[10]</span></a></span></p>

<p>Bivalirudin is an anticoagulant. Therefore, bleeding is an expected adverse event.  In clinical trials, bivalirudin treated patients exhibited statistically significantly lower rates of bleeding than patients treated with heparin plus a GP IIb/IIIa inhibitor. The most common (≥10%) adverse events of bivalirudin are back pain, pain, nausea, headache, and hypotension.<span class="mw-ref" id="cite_ref-Angiomax_1-15"><a href="#cite_note-Angiomax-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span><span class="mw-ref" id="cite_ref-Angiox_10-6"><a href="#cite_note-Angiox-10" style="counter-reset: mw-Ref 10;"><span class="mw-reflink-text">[10]</span></a></span></p>

<p>Bivalirudin is classified as Pregnancy Category B.<span class="mw-ref" id="cite_ref-Angiomax_1-16"><a href="#cite_note-Angiomax-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span><span class="mw-ref" id="cite_ref-Angiox_10-7"><a href="#cite_note-Angiox-10" style="counter-reset: mw-Ref 10;"><span class="mw-reflink-text">[10]</span></a></span></p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Pediatric_experience">Pediatric experience</h2></summary>
    

<p>The U.S. Food and Drug Administration (FDA) granted pediatric exclusivity for bivalirudin, based on studies submitted in response to a written request by the FDA to investigate the use of bivalirudin in pediatric patients aged birth to 16-years old.</p>

<p>The submission was based on a prospective, open-label, multi-center, single arm study evaluating bivalirudin as a procedural anticoagulant in the pediatric population undergoing intravascular procedures for congenital heart disease.</p>

<p>Study outcomes suggest that the pharmacokinetic (PK) and pharmacodynamic (PD) response of bivalirudin in the pediatric population is predictable and behaves in a manner similar to that in adults.<span class="mw-ref" id="cite_ref-Zamora2009_12-0"><a href="#cite_note-Zamora2009-12" style="counter-reset: mw-Ref 12;"><span class="mw-reflink-text">[12]</span></a></span></p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Comparative_results">Comparative results</h2></summary>
    

<p>Bivalirudin is supported by 7 major randomized trials. These trials include REPLACE-2 (Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events-2), BAT (Bivalirudin Angioplasty Trial), ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy Trial), and HORIZONS AMI (Harmonizing Outcomes With Revascularization and Stents in AMI).  A total of 25,000 patients with a low to high risk for ischemic complications undergoing PCI were evaluated.  Bivalirudin with or without provisional GPIIb/IIIa demonstrated similar angiographic and procedural outcomes and improved clinical outcomes when compared with heparin plus GPIIb/IIIa.<span class="mw-ref" id="cite_ref-Angiomax_1-17"><a href="#cite_note-Angiomax-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span><span class="mw-ref" id="cite_ref-Stone2006_4-2"><a href="#cite_note-Stone2006-4" style="counter-reset: mw-Ref 4;"><span class="mw-reflink-text">[4]</span></a></span><span class="mw-ref" id="cite_ref-Bittl2001_6-1"><a href="#cite_note-Bittl2001-6" style="counter-reset: mw-Ref 6;"><span class="mw-reflink-text">[6]</span></a></span><span class="mw-ref" id="cite_ref-Lincoff2003_7-1"><a href="#cite_note-Lincoff2003-7" style="counter-reset: mw-Ref 7;"><span class="mw-reflink-text">[7]</span></a></span><span class="mw-ref" id="cite_ref-Stone2008_13-0"><a href="#cite_note-Stone2008-13" style="counter-reset: mw-Ref 13;"><span class="mw-reflink-text">[13]</span></a></span></p>

<p><b>HORIZONS-AMI</b><span class="mw-ref" id="cite_ref-Stone2008_13-1"><a href="#cite_note-Stone2008-13" style="counter-reset: mw-Ref 13;"><span class="mw-reflink-text">[13]</span></a></span><span class="mw-ref" id="cite_ref-Mehran2009_14-0"><a href="#cite_note-Mehran2009-14" style="counter-reset: mw-Ref 14;"><span class="mw-reflink-text">[14]</span></a></span><span class="mw-ref" id="cite_ref-Stone2009_15-0"><a href="#cite_note-Stone2009-15" style="counter-reset: mw-Ref 15;"><span class="mw-reflink-text">[15]</span></a></span></p>

<p>HORIZONS AMI was a prospective, randomized, open-label, double-arm multicenter trial in STEMI patients undergoing primary PCI.</p>

<p><i>30 Day Results</i></p>

<ul><li>The incidence of net adverse clinical events (9.2% vs. 12.1%) and major bleeding (4.9% vs. 8.3%) was significantly reduced by bivalirudin monotherapy versus unfractionated heparin (UFH) plus a GP IIb/IIIa inhibitor with similar rates of major adverse cardiovascular events (5.4 vs. 5.5%) at 30 days.</li>
<li>A significant reduction in the rate of cardiac mortality in patients treated with bivalirudin monotherapy versus UFH plus a GP IIb/IIIa inhibitor was observed (1.8% vs. 2.9%) at 30 days.</li>
<li>Patients receiving Angiomax monotherapy had similar rates of overall stent thrombosis (Academic Research Consortium (ARC) definition) at 30 days versus UFH plus a GP IIb/IIIa inhibitor (2.5% vs. 1.9%), with the exception of acute stent thrombosis (&lt;24 hours), which was higher for the bivalirudin-treated patients at 1.3% vs 0.3% for the UFH-GP IIb/IIIa-inhibitor-treated patients.</li></ul>

<p><i>1-Year Results</i></p>

<ul><li>At 1-year follow-up, a reduction in the incidence of net adverse clinical events (15.7% vs. 18.3%) and major bleeding (5.8% vs. 4.9%) was maintained in the bivalirudin monotherapy group versus UFH plus a GP IIb/IIIa inhibitor group, with no difference in the rate of major adverse cardiovascular events (11.9% vs. 11.9%)</li>
<li>A significant reduction in the rate of cardiac mortality in patients treated with bivalirudin monotherapy versus UFH plus a GP IIb/IIIa inhibitor was maintained at 1 year in the HORIZONS AMI trial (2.1% vs. 3.8%)The incidence of stent thrombosis  at 1 year was also similar between the 2 treatment groups (3.5% in the Angiomax group vs. 3.2% in the UFH plus GP IIb/IIIa inhibitor group).</li></ul>

<p><i>2-Year Results</i></p>

<ul><li>At 2-year follow-up, a reduction in the incidence of net adverse clinical events (22.3% vs. 24.8%) and major bleeding (6.4% vs. 9.6%) was maintained in the bivalirudin monotherapy group versus UFH plus a GP IIb/IIIa inhibitor group, with no difference in the rate of major adverse cardiovascular events (18.7% vs. 18.8%)</li>
<li>A significant reduction in the rate of cardiac mortality in patients treated with bivalirudin monotherapy versus UFH plus a GP IIb/IIIa inhibitor was maintained at 2 year in the HORIZONS AMI trial (2.5% vs. 4.2%)</li>
<li>At  2-year follow-up, treatment with bivalirudin monotherapy resulted in a 25% reduction in all-cause mortality, representing 15 lives saved per 1000 patients treated (number needed to treat [NNT] = 67 to save 1 life).</li>
<li>The incidence of stent thrombosis (ARC definite/probable) at 2 years was also similar between the 2 treatment groups (4.6% in the Angiomax group vs. 4.3% in the UFH plus GP IIb/IIIa inhibitor group).</li></ul>

<p><b>ACUITY</b><span class="mw-ref" id="cite_ref-Stone2006_4-3"><a href="#cite_note-Stone2006-4" style="counter-reset: mw-Ref 4;"><span class="mw-reflink-text">[4]</span></a></span></p>

<p>ACUITY was a large multicenter, prospective, open-label, 3-arm trial designed to establish the optimal antithrombotic treatment regimens in patients with UA/NSTEMI undergoing early invasive management.</p>

<p><i>30-Day Results</i></p>

<ul><li>Bivalirudin monotherapy provided superior net clinical outcomes compared to any heparin regimen with GP IIb/IIIa inhibitor (10.1% vs 11.7%) at 30 days.</li>
<li>The incidence of ACUITY scale major bleeding (non-CABG) was decreased significantly by 47% in the bivalirudin monotherapy group vs the heparin with GP IIb/IIIa inhibitor group (3.0% vs 5.7%) at 30 days.</li></ul>

<p><i>1-Year Results</i></p>

<ul><li>Bivalirudin alone demonstrated no difference in the rates of composite ischemic complications (death, MI, unplanned revascularization for ischemia) versus heparin with GP IIb/IIIa inhibition (16.4% vs 16.3%) at 12 months.</li></ul>

<p><b>REPLACE-2</b><span class="mw-ref" id="cite_ref-Lincoff2003_7-2"><a href="#cite_note-Lincoff2003-7" style="counter-reset: mw-Ref 7;"><span class="mw-reflink-text">[7]</span></a></span></p>

<p>REPLACE-2 was a multicenter, double-blind, triple-dummy randomized clinical trial in patients with low to moderate risk for ischemic complications undergoing PCI.</p>

<p><i>30 Days</i></p>

<ul><li>The incidence of net adverse clinical events (9.2% vs. 10.0%) and major adverse cardiovascular events (7.6% vs. 7.1%) was reduced by bivalirudin monotherapy versus unfractionated heparin (UFH) plus a GP IIb/IIIa inhibitor with significant reduction in rates of major bleeding (2.4 vs. 4.1%) at 30 days.</li></ul>

<p><i>1-Year Results</i></p>

<ul><li>Differences in mortality favoring bivalirudin at 30 days and 6 months was maintained at 12 months and demonstrated a 24% risk reduction in death compared to heparin plus GP IIb/IIIa inhibition.</li></ul>

<p><b>BAT</b><span class="mw-ref" id="cite_ref-Bittl2001_6-2"><a href="#cite_note-Bittl2001-6" style="counter-reset: mw-Ref 6;"><span class="mw-reflink-text">[6]</span></a></span></p>

<p>The Phase III Bivalirudin Angioplasty Trial (BAT) was a randomized, prospective, double blind, multicenter study in patients with unstable angina undergoing PTCA.</p>

<ul><li>The composite endpoint of death, MI or revascularization occurred in 6.2%  of patients treated with bivalirudin and in 7.9% of patients treated with heparin.</li>
<li>Significant reductions in clinical events were maintained at 90 days with absolute benefits being sustained through 180 days.</li>
<li>The incidence of major hemorrhage for the entire hospitalization period in patients assigned bivalirudin was 3.7% compared to 9.3% in patients randomized to heparin.</li></ul>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Guidelines">Guidelines</h2></summary>
    

<p>Bivalirudin has Class I recommendations in multiple national guidelines.</p>

<p><b>US guidelines</b><span class="mw-ref" id="cite_ref-Kushner2009_16-0"><a href="#cite_note-Kushner2009-16" style="counter-reset: mw-Ref 16;"><span class="mw-reflink-text">[16]</span></a></span><span class="mw-ref" id="cite_ref-Anderson2007_17-0"><a href="#cite_note-Anderson2007-17" style="counter-reset: mw-Ref 17;"><span class="mw-reflink-text">[17]</span></a></span><span class="mw-ref" id="cite_ref-Harrington2008_18-0"><a href="#cite_note-Harrington2008-18" style="counter-reset: mw-Ref 18;"><span class="mw-reflink-text">[18]</span></a></span></p>

<table class="wikitable">
<tbody><tr>
<th>Patient Type</th>
<th>Guidelines</th>
<th>Recommendations</th></tr>
<tr>
<td>STEMI and primary PCI</td>
<td>ACC/AHA/SCAI 2009 Joint STEMI/PCI Focused Update</td>
<td>Class I-B, IIa-B</td></tr>
<tr>
<td>UA/NSTEMI</td>
<td>ACC/AHA 2007 guidelines for UA/NSTEMI patients</td>
<td>Class I-B, IIa-B</td></tr>
<tr> 
<td>NSTE-ACS patients</td>
<td>ACCP 2008 clinical practice guidelines for patients with NSTE-ACS</td>
<td>Grade 1A, 2B</td></tr>
<tr> 
<td>PCI</td>
<td>ACCP 2008 clinical practice guidelines for patients with NSTE-ACS</td>
<td>Grade 1B</td></tr>
</tbody></table>

<p><b>EU guidelines</b><span class="mw-ref" id="cite_ref-Silber2005_19-0"><a href="#cite_note-Silber2005-19" style="counter-reset: mw-Ref 19;"><span class="mw-reflink-text">[19]</span></a></span><span class="mw-ref" id="cite_ref-Bassand2008_20-0"><a href="#cite_note-Bassand2008-20" style="counter-reset: mw-Ref 20;"><span class="mw-reflink-text">[20]</span></a></span><span class="mw-ref" id="cite_ref-VandeWerf2008_21-0"><a href="#cite_note-VandeWerf2008-21" style="counter-reset: mw-Ref 21;"><span class="mw-reflink-text">[21]</span></a></span></p>

<table class="wikitable">
<tbody><tr>
<th>Patient Type</th>
<th>Guidelines</th>
<th>Recommendations</th></tr>
<tr>
<td>STEMI</td>
<td>European Society of Cardiology 2008</td>
<td>Class IIa – B</td></tr>
<tr>
<td>NSTE-ACS</td>
<td>European Society of Cardiology 2007</td>
<td>Class IIa-B, IB</td></tr>
<tr>
<td>PCI</td>
<td>European Society of Cardiology 2005</td>
<td>Class IIa C, IC</td></tr>
</tbody></table>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="See_also">See also</h2></summary>
    
<ul><li>Discovery and development of direct thrombin inhibitors</li></ul>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="References">References</h2></summary>
    
<div class="reflist " style=" list-style-type: decimal;">
<div class="mw-references-wrap mw-references-columns"><ol class="mw-references references"><li id="cite_note-Angiomax-1"> <span id="mw-reference-text-cite_note-Angiomax-1" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://web.archive.org/web/20120426012238/http://angiomax.com/Downloads/Angiomax_PI_2010_PN1601-12.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20120426012238/http://angiomax.com/Downloads/Angiomax_PI_2010_PN1601-12.pdf'" tppabs="https://web.archive.org/web/20120426012238/http://angiomax.com/Downloads/Angiomax_PI_2010_PN1601-12.pdf" class="external text external">"Angiomax (bivalirudin) Prescribing Information"</a> <span class="cs1-format">(PDF)</span>. The Medicines Company. Archived from <a href="javascript:if(confirm('http://angiomax.com/Downloads/Angiomax_PI_2010_PN1601-12.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://angiomax.com/Downloads/Angiomax_PI_2010_PN1601-12.pdf'" tppabs="http://angiomax.com/Downloads/Angiomax_PI_2010_PN1601-12.pdf" class="external text external">the original</a> <span class="cs1-format">(PDF)</span> on April 26, 2012<span class="reference-accessdate">. Retrieved <span class="nowrap">2 December</span> 2011</span>.</cite></span></li><li id="cite_note-Anand2007-2"> <span id="mw-reference-text-cite_note-Anand2007-2" class="mw-reference-text"><cite id="CITEREFAnandKimKamranSharma2007" class="citation journal cs1">Anand SX, Kim MC, Kamran M, Sharma SK, Kini AS, Fareed J,  et al. (August 2007). "Comparison of platelet function and morphology in patients undergoing percutaneous coronary intervention receiving bivalirudin versus unfractionated heparin versus clopidogrel pretreatment and bivalirudin". <i>The American Journal of Cardiology</i>. <b>100</b> (3): 417–24. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.amjcard.2007.02.106  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.amjcard.2007.02.106'" tppabs="https://doi.org/10.1016%2Fj.amjcard.2007.02.106" class="external text external">10.1016/j.amjcard.2007.02.106</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/17659921  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/17659921'" tppabs="https://pubmed.ncbi.nlm.nih.gov/17659921" class="external text external">17659921</a>.</cite></span></li><li id="cite_note-Weitz1990-3"> <span id="mw-reference-text-cite_note-Weitz1990-3" class="mw-reference-text"><cite id="CITEREFWeitzHudobaMasselMaraganore1990" class="citation journal cs1">Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J (August 1990). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC296739  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC296739'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC296739" class="external text external">"Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors"</a>. <i>The Journal of Clinical Investigation</i>. <b>86</b> (2): 385–91. doi:<a href="javascript:if(confirm('https://doi.org/10.1172%2FJCI114723  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1172%2FJCI114723'" tppabs="https://doi.org/10.1172%2FJCI114723" class="external text external">10.1172/JCI114723</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC296739  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC296739'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC296739" class="external text external">296739</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/2384594  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/2384594'" tppabs="https://pubmed.ncbi.nlm.nih.gov/2384594" class="external text external">2384594</a>.</cite></span></li><li id="cite_note-Stone2006-4"> <span id="mw-reference-text-cite_note-Stone2006-4" class="mw-reference-text"><cite id="CITEREFStoneMcLaurinCoxBertrand2006" class="citation journal cs1">Stone GW, McLaurin BT, Cox DA, Bertrand ME, Lincoff AM, Moses JW,  et al. (November 2006). <a href="javascript:if(confirm('http://diposit.ub.edu/dspace/bitstream/2445/49765/1/633096.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://diposit.ub.edu/dspace/bitstream/2445/49765/1/633096.pdf'" tppabs="http://diposit.ub.edu/dspace/bitstream/2445/49765/1/633096.pdf" class="external text external">"Bivalirudin for patients with acute coronary syndromes"</a> <span class="cs1-format">(PDF)</span>. <i>The New England Journal of Medicine</i>. <b>355</b> (21): 2203–16. doi:<a href="javascript:if(confirm('https://doi.org/10.1056%2FNEJMoa062437  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1056%2FNEJMoa062437'" tppabs="https://doi.org/10.1056%2FNEJMoa062437" class="external text external">10.1056/NEJMoa062437</a>. hdl:<a href="javascript:if(confirm('https://hdl.handle.net/2445%2F49765  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://hdl.handle.net/2445%2F49765'" tppabs="https://hdl.handle.net/2445%2F49765" class="external text external">2445/49765</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/17124018  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/17124018'" tppabs="https://pubmed.ncbi.nlm.nih.gov/17124018" class="external text external">17124018</a>.</cite></span></li><li id="cite_note-Weitz2002-5"> <span id="mw-reference-text-cite_note-Weitz2002-5" class="mw-reference-text"><cite id="CITEREFWeitzBates2002" class="citation journal cs1">Weitz JI, Bates SM (April 2002). "Acute coronary syndromes: a focus on thrombin". <i>The Journal of Invasive Cardiology</i>. 14 Suppl B: 2B–7B. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/11967385  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/11967385'" tppabs="https://pubmed.ncbi.nlm.nih.gov/11967385" class="external text external">11967385</a>.</cite></span></li><li id="cite_note-Bittl2001-6"> <span id="mw-reference-text-cite_note-Bittl2001-6" class="mw-reference-text"><cite id="CITEREFBittlChaitmanFeitKimball2001" class="citation journal cs1">Bittl JA, Chaitman BR, Feit F, Kimball W, Topol EJ (December 2001). "Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: Final report reanalysis of the Bivalirudin Angioplasty Study". <i>American Heart Journal</i>. <b>142</b> (6): 952–9. doi:<a href="javascript:if(confirm('https://doi.org/10.1067%2Fmhj.2001.119374  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1067%2Fmhj.2001.119374'" tppabs="https://doi.org/10.1067%2Fmhj.2001.119374" class="external text external">10.1067/mhj.2001.119374</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/11717596  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/11717596'" tppabs="https://pubmed.ncbi.nlm.nih.gov/11717596" class="external text external">11717596</a>.</cite></span></li><li id="cite_note-Lincoff2003-7"> <span id="mw-reference-text-cite_note-Lincoff2003-7" class="mw-reference-text"><cite id="CITEREFLincoffBittlHarringtonFeit2003" class="citation journal cs1">Lincoff AM, Bittl JA, Harrington RA, Feit F, Kleiman NS, Jackman JD,  et al. (February 2003). <a href="javascript:if(confirm('https://doi.org/10.1001/jama.289.7.853  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1001/jama.289.7.853'" tppabs="https://doi.org/10.1001/jama.289.7.853" class="external text external">"Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial"</a>. <i>JAMA</i>. <b>289</b> (7): 853–63. doi:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://doi.org/10.1001%2Fjama.289.7.853  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1001%2Fjama.289.7.853'" tppabs="https://doi.org/10.1001%2Fjama.289.7.853" class="external text external">10.1001/jama.289.7.853</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/12588269  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/12588269'" tppabs="https://pubmed.ncbi.nlm.nih.gov/12588269" class="external text external">12588269</a>.</cite></span></li><li id="cite_note-8"> <span id="mw-reference-text-cite_note-8" class="mw-reference-text"><cite id="CITEREFBrauser2015" class="citation news cs1">Brauser D (2015-04-13). <a href="javascript:if(confirm('http://www.medscape.com/viewarticle/843024  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.medscape.com/viewarticle/843024'" tppabs="http://www.medscape.com/viewarticle/843024" class="external text external">"BRIGHT in Print: Bivalirudin Bests Heparin for Fewer Bleeding Events During PCI, but Dose Matters"</a>. Medscape<span class="reference-accessdate">. Retrieved <span class="nowrap">14 April</span> 2015</span>.</cite></span></li><li id="cite_note-9"> <span id="mw-reference-text-cite_note-9" class="mw-reference-text"><span>Clinical trial number </span><i><a href="javascript:if(confirm('https://www.clinicaltrials.gov/show/NCT01696110  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.clinicaltrials.gov/show/NCT01696110'" tppabs="https://www.clinicaltrials.gov/show/NCT01696110" class="external text external">NCT01696110</a></i><span> for "BivaliRudin in Acute Myocardial Infarction vs Glycoprotein IIb/IIIa and Heparin :a Randomised Controlled Trial. (BRIGHT)" at </span>ClinicalTrials.gov</span></li><li id="cite_note-Angiox-10"> <span id="mw-reference-text-cite_note-Angiox-10" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://web.archive.org/web/20120426012235/http://www.themedicinescompany.com/new-images/Angiox-PIs/emea-combined-h562en.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20120426012235/http://www.themedicinescompany.com/new-images/Angiox-PIs/emea-combined-h562en.pdf'" tppabs="https://web.archive.org/web/20120426012235/http://www.themedicinescompany.com/new-images/Angiox-PIs/emea-combined-h562en.pdf" class="external text external">"Annex 1 - Summary of Product Characteristics"</a> <span class="cs1-format">(PDF)</span>. <i>www.themedicinescompany.com</i>. The Medicines Company UK Ltd. March 2010. Archived from <a href="javascript:if(confirm('http://www.themedicinescompany.com/new-images/Angiox-PIs/emea-combined-h562en.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.themedicinescompany.com/new-images/Angiox-PIs/emea-combined-h562en.pdf'" tppabs="http://www.themedicinescompany.com/new-images/Angiox-PIs/emea-combined-h562en.pdf" class="external text external">the original</a> <span class="cs1-format">(PDF)</span> on 26 April 2012<span class="reference-accessdate">. Retrieved <span class="nowrap">2 December</span> 2011</span>.</cite></span></li><li id="cite_note-11"> <span id="mw-reference-text-cite_note-11" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://web.archive.org/web/20150203135952/http://angiomax.com/downloads/Angiomax_US_PI_June_2013.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20150203135952/http://angiomax.com/downloads/Angiomax_US_PI_June_2013.pdf'" tppabs="https://web.archive.org/web/20150203135952/http://angiomax.com/downloads/Angiomax_US_PI_June_2013.pdf" class="external text external">"Angiomax US PI June 2013"</a> <span class="cs1-format">(PDF)</span>. <i>Angiomax.com</i>. Archived from <a href="javascript:if(confirm('http://www.angiomax.com/downloads/Angiomax_US_PI_June_2013.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.angiomax.com/downloads/Angiomax_US_PI_June_2013.pdf'" tppabs="http://www.angiomax.com/downloads/Angiomax_US_PI_June_2013.pdf" class="external text external">the original</a> <span class="cs1-format">(PDF)</span> on 2015-02-03.</cite></span></li><li id="cite_note-Zamora2009-12"> <span id="mw-reference-text-cite_note-Zamora2009-12" class="mw-reference-text"><cite id="CITEREFZamoraForbesHijaziQureshi2009" class="citation journal cs1">Zamora R, Forbes T, Hijazi Z, Qureshi A, Ringewald J, Rome J, Vincent R (2009). "Bivalirudin (Angiomax®) As a Procedural Anticoagulant in the Pediatric Population Undergoing Intravascular Procedures for Congenital Heart Disease". <i>Catheterization and Cardiovascular Interventions</i>. <b>73</b> (S1): S8.</cite></span></li><li id="cite_note-Stone2008-13"> <span id="mw-reference-text-cite_note-Stone2008-13" class="mw-reference-text"><cite id="CITEREFStoneWitzenbichlerGuagliumiPeruga2008" class="citation journal cs1">Stone GW, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D,  et al. (May 2008). <a href="javascript:if(confirm('http://researchonline.lshtm.ac.uk/7561/1/nejmoa0708191.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://researchonline.lshtm.ac.uk/7561/1/nejmoa0708191.pdf'" tppabs="http://researchonline.lshtm.ac.uk/7561/1/nejmoa0708191.pdf" class="external text external">"Bivalirudin during primary PCI in acute myocardial infarction"</a> <span class="cs1-format">(PDF)</span>. <i>The New England Journal of Medicine</i>. <b>358</b> (21): 2218–30. doi:<a href="javascript:if(confirm('https://doi.org/10.1056%2FNEJMoa0708191  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1056%2FNEJMoa0708191'" tppabs="https://doi.org/10.1056%2FNEJMoa0708191" class="external text external">10.1056/NEJMoa0708191</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/18499566  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/18499566'" tppabs="https://pubmed.ncbi.nlm.nih.gov/18499566" class="external text external">18499566</a>.</cite></span></li><li id="cite_note-Mehran2009-14"> <span id="mw-reference-text-cite_note-Mehran2009-14" class="mw-reference-text"><cite id="CITEREFMehranLanskyWitzenbichlerGuagliumi2009" class="citation journal cs1">Mehran R, Lansky AJ, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR,  et al. (October 2009). "Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial". <i>Lancet</i>. <b>374</b> (9696): 1149–59. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2FS0140-6736%2809%2961484-7  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2FS0140-6736%2809%2961484-7'" tppabs="https://doi.org/10.1016%2FS0140-6736%2809%2961484-7" class="external text external">10.1016/S0140-6736(09)61484-7</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/19717185  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/19717185'" tppabs="https://pubmed.ncbi.nlm.nih.gov/19717185" class="external text external">19717185</a>.</cite></span></li><li id="cite_note-Stone2009-15"> <span id="mw-reference-text-cite_note-Stone2009-15" class="mw-reference-text"><cite id="CITEREFGregg_W._Stone2009" class="citation conference cs1">Gregg W. Stone (25 September 2009). <i>HORIZONS- AMI: Two-Year Follow-up from a Prospective, Randomized Trial of Heparin Plus Glycoprotein IIb/IIIa Inhibitors vs. Bivalirudin and Paclitaxel-Eluting vs. Bare-Metal Stents in STEMI</i>. TCT2009 Conference, San Francisco.</cite></span></li><li id="cite_note-Kushner2009-16"> <span id="mw-reference-text-cite_note-Kushner2009-16" class="mw-reference-text"><cite id="CITEREFKushnerHandSmithKing2009" class="citation journal cs1">Kushner FG, Hand M, Smith SC, King SB, Anderson JL, Antman EM,  et al. (December 2009). "2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update) a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines". <i>Journal of the American College of Cardiology</i>. <b>54</b> (23): 2205–41. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.jacc.2009.10.015  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.jacc.2009.10.015'" tppabs="https://doi.org/10.1016%2Fj.jacc.2009.10.015" class="external text external">10.1016/j.jacc.2009.10.015</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/19942100  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/19942100'" tppabs="https://pubmed.ncbi.nlm.nih.gov/19942100" class="external text external">19942100</a>.</cite></span></li><li id="cite_note-Anderson2007-17"> <span id="mw-reference-text-cite_note-Anderson2007-17" class="mw-reference-text"><cite id="CITEREFAndersonAdamsAntmanBridges2007" class="citation journal cs1">Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE,  et al. (August 2007). <a href="javascript:if(confirm('https://doi.org/10.1016/j.jacc.2007.02.013  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016/j.jacc.2007.02.013'" tppabs="https://doi.org/10.1016/j.jacc.2007.02.013" class="external text external">"ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine"</a>. <i>Journal of the American College of Cardiology</i>. <b>50</b> (7): e1–e157. doi:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.jacc.2007.02.013  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.jacc.2007.02.013'" tppabs="https://doi.org/10.1016%2Fj.jacc.2007.02.013" class="external text external">10.1016/j.jacc.2007.02.013</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/17692738  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/17692738'" tppabs="https://pubmed.ncbi.nlm.nih.gov/17692738" class="external text external">17692738</a>.</cite></span></li><li id="cite_note-Harrington2008-18"> <span id="mw-reference-text-cite_note-Harrington2008-18" class="mw-reference-text"><cite id="CITEREFHarringtonBeckerCannonGutterman2008" class="citation journal cs1">Harrington RA, Becker RC, Cannon CP, Gutterman D, Lincoff AM, Popma JJ,  et al. (June 2008). "Antithrombotic therapy for non-ST-segment elevation acute coronary syndromes: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)". <i>Chest</i>. <b>133</b> (6 Suppl): 670S–707S. doi:<a href="javascript:if(confirm('https://doi.org/10.1378%2Fchest.08-0691  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1378%2Fchest.08-0691'" tppabs="https://doi.org/10.1378%2Fchest.08-0691" class="external text external">10.1378/chest.08-0691</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/18574276  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/18574276'" tppabs="https://pubmed.ncbi.nlm.nih.gov/18574276" class="external text external">18574276</a>.</cite></span></li><li id="cite_note-Silber2005-19"> <span id="mw-reference-text-cite_note-Silber2005-19" class="mw-reference-text"><cite id="CITEREFSilberAlbertssonAvilésCamici2005" class="citation journal cs1">Silber S, Albertsson P, Avilés FF, Camici PG, Colombo A, Hamm C,  et al. (April 2005). <a href="javascript:if(confirm('https://doi.org/10.1093/eurheartj/ehi138  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1093/eurheartj/ehi138'" tppabs="https://doi.org/10.1093/eurheartj/ehi138" class="external text external">"Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology"</a>. <i>European Heart Journal</i>. <b>26</b> (8): 804–47. doi:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://doi.org/10.1093%2Feurheartj%2Fehi138  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1093%2Feurheartj%2Fehi138'" tppabs="https://doi.org/10.1093%2Feurheartj%2Fehi138" class="external text external">10.1093/eurheartj/ehi138</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/15769784  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/15769784'" tppabs="https://pubmed.ncbi.nlm.nih.gov/15769784" class="external text external">15769784</a>.</cite></span></li><li id="cite_note-Bassand2008-20"> <span id="mw-reference-text-cite_note-Bassand2008-20" class="mw-reference-text"><cite id="CITEREFBassandHammArdissinoBoersma2007" class="citation journal cs1">Bassand JP, Hamm CW, Ardissino D, Boersma E, Budaj A, Fernández-Avilés F,  et al. (July 2007). <a href="javascript:if(confirm('https://doi.org/10.1093/eurheartj/ehm161  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1093/eurheartj/ehm161'" tppabs="https://doi.org/10.1093/eurheartj/ehm161" class="external text external">"Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes"</a>. <i>European Heart Journal</i>. <b>28</b> (13): 1598–660. doi:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://doi.org/10.1093%2Feurheartj%2Fehm161  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1093%2Feurheartj%2Fehm161'" tppabs="https://doi.org/10.1093%2Feurheartj%2Fehm161" class="external text external">10.1093/eurheartj/ehm161</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/17569677  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/17569677'" tppabs="https://pubmed.ncbi.nlm.nih.gov/17569677" class="external text external">17569677</a>.</cite></span></li><li id="cite_note-VandeWerf2008-21"> <span id="mw-reference-text-cite_note-VandeWerf2008-21" class="mw-reference-text"><cite id="CITEREFVan_de_WerfBaxBetriuBlomstrom-Lundqvist2008" class="citation journal cs1">Van de Werf F, Bax J, Betriu A, Blomstrom-Lundqvist C, Crea F, Falk V,  et al. (December 2008). <a href="javascript:if(confirm('https://doi.org/10.1093/eurheartj/ehn416  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1093/eurheartj/ehn416'" tppabs="https://doi.org/10.1093/eurheartj/ehn416" class="external text external">"Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology"</a>. <i>European Heart Journal</i>. <b>29</b> (23): 2909–45. doi:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://doi.org/10.1093%2Feurheartj%2Fehn416  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1093%2Feurheartj%2Fehn416'" tppabs="https://doi.org/10.1093%2Feurheartj%2Fehn416" class="external text external">10.1093/eurheartj/ehn416</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/19004841  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/19004841'" tppabs="https://pubmed.ncbi.nlm.nih.gov/19004841" class="external text external">19004841</a>.</cite></span></li></ol></div></div>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="External_links">External links</h2></summary>
    
<ul><li><a href="javascript:if(confirm('http://www.dicardiology.com/article/heparin-more-effective-bivalirudin-treating-patients-during-pci  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.dicardiology.com/article/heparin-more-effective-bivalirudin-treating-patients-during-pci'" tppabs="http://www.dicardiology.com/article/heparin-more-effective-bivalirudin-treating-patients-during-pci" class="external text external">Heparin More Effective Than Bivalirudin in Treating Patients During PCI - Diagnostic and interventional cardiology magazine</a></li></ul>

<div role="navigation" class="navbox" aria-labelledby="Antithrombotics_(thrombolytics,_anticoagulants_and_antiplatelet_drugs)_(B01)" style="padding:3px"><table class="nowraplinks hlist mw-collapsible autocollapse navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><div id="Antithrombotics_(thrombolytics,_anticoagulants_and_antiplatelet_drugs)_(B01)" style="font-size:114%;margin:0 4em">Antithrombotics (thrombolytics, anticoagulants and antiplatelet drugs) (B01)</div></th></tr><tr><th scope="row" class="navbox-group" style="width:1%">Antiplatelet drugs</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%">Glycoprotein IIb/IIIa inhibitors</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Abciximab.htm" tppabs="https://ptable.com/wiki/compounds/A/Abciximab" title="Abciximab">Abciximab</a></li>
<li><a href="Eptifibatide.htm" tppabs="https://ptable.com/wiki/compounds/A/Eptifibatide" title="Eptifibatide">Eptifibatide</a></li>
<li><span class="new">Orbofiban</span></li>
<li><span class="new">Roxifiban</span></li>
<li>Sibrafiban<sup>§</sup></li>
<li><a href="Tirofiban.htm" tppabs="https://ptable.com/wiki/compounds/A/Tirofiban" title="Tirofiban">Tirofiban</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">ADP receptor/P2Y<sub>12</sub> inhibitors</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Thienopyridines
<ul><li><a href="Clopidogrel.htm" tppabs="https://ptable.com/wiki/compounds/A/Clopidogrel" title="Clopidogrel">Clopidogrel</a></li>
<li>Prasugrel</li>
<li><a href="Ticlopidine.htm" tppabs="https://ptable.com/wiki/compounds/A/Ticlopidine" title="Ticlopidine">Ticlopidine</a></li></ul></li>
<li>Nucleotide/nucleoside analogs
<ul><li>Cangrelor</li>
<li>Elinogrel</li>
<li>Ticagrelor</li></ul></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Prostaglandin analogue (<a href="Prostacyclin.htm" tppabs="https://ptable.com/wiki/compounds/A/Prostacyclin" title="Prostacyclin">PGI2</a>)</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Beraprost</li>
<li><a href="Iloprost.htm" tppabs="https://ptable.com/wiki/compounds/A/Iloprost" title="Iloprost">Iloprost</a></li>
<li><a href="Prostacyclin.htm" tppabs="https://ptable.com/wiki/compounds/A/Prostacyclin" title="Prostacyclin">Prostacyclin</a></li>
<li><a href="Treprostinil.htm" tppabs="https://ptable.com/wiki/compounds/A/Treprostinil" title="Treprostinil">Treprostinil</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">COX inhibitors</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Aspirin.htm" tppabs="https://ptable.com/wiki/compounds/A/Aspirin" title="Aspirin">Acetylsalicylic acid/Aspirin</a><sup>#</sup></li>
<li>Aloxiprin</li>
<li>Carbasalate calcium</li>
<li>Indobufen</li>
<li>Triflusal</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Thromboxane inhibitors</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Thromboxane synthase inhibitors
<ul><li><a href="Dipyridamole.htm" tppabs="https://ptable.com/wiki/compounds/A/Dipyridamole" title="Dipyridamole">Dipyridamole</a> (+ aspirin)</li>
<li><a href="Picotamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Picotamide" title="Picotamide">Picotamide</a></li>
<li>Terbogrel</li></ul></li>
<li>Receptor antagonists
<ul><li>Terbogrel</li>
<li>Terutroban<sup>§</sup></li></ul></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Phosphodiesterase inhibitors</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Cilostazol.htm" tppabs="https://ptable.com/wiki/compounds/A/Cilostazol" title="Cilostazol">Cilostazol</a></li>
<li><a href="Dipyridamole.htm" tppabs="https://ptable.com/wiki/compounds/A/Dipyridamole" title="Dipyridamole">Dipyridamole</a></li>
<li>Triflusal</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Other</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Cloricromen</li>
<li>Ditazole</li>
<li>Vorapaxar</li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Anticoagulants</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%">Vitamin K antagonists<br>(inhibit <a href="Thrombin.htm" tppabs="https://ptable.com/wiki/compounds/A/Thrombin" title="Thrombin">II</a>, VII, IX, X)</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Coumarin.htm" tppabs="https://ptable.com/wiki/compounds/A/Coumarin" title="Coumarin">Coumarins</a>: <a href="Acenocoumarol.htm" tppabs="https://ptable.com/wiki/compounds/A/Acenocoumarol" title="Acenocoumarol">Acenocoumarol</a></li>
<li><a href="Coumatetralyl.htm" tppabs="https://ptable.com/wiki/compounds/A/Coumatetralyl" title="Coumatetralyl">Coumatetralyl</a></li>
<li><a href="Dicoumarol.htm" tppabs="https://ptable.com/wiki/compounds/A/Dicoumarol" title="Dicoumarol">Dicoumarol</a></li>
<li>Ethyl biscoumacetate</li>
<li><a href="Phenprocoumon.htm" tppabs="https://ptable.com/wiki/compounds/A/Phenprocoumon" title="Phenprocoumon">Phenprocoumon</a></li>
<li><a href="Warfarin.htm" tppabs="https://ptable.com/wiki/compounds/A/Warfarin" title="Warfarin">Warfarin</a><sup>#</sup></li>
<li><a href="1,3-Indandione.htm" tppabs="https://ptable.com/wiki/compounds/A/1%2C3-Indandione" title="1,3-Indandione">1,3-Indandiones</a>: Clorindione</li>
<li><a href="Diphenadione.htm" tppabs="https://ptable.com/wiki/compounds/A/Diphenadione" title="Diphenadione">Diphenadione</a></li>
<li><a href="Phenindione.htm" tppabs="https://ptable.com/wiki/compounds/A/Phenindione" title="Phenindione">Phenindione</a></li>
<li>Other: Tioclomarol</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Factor Xa inhibitors<br>(with some II inhibition)</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%"><a href="Heparin.htm" tppabs="https://ptable.com/wiki/compounds/A/Heparin" title="Heparin">Heparin</a> group/<br>glycosaminoglycans/<br>(bind antithrombin)</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Low-molecular-weight heparin
<ul><li>Bemiparin</li>
<li>Certoparin</li>
<li><a href="Dalteparin_sodium.htm" tppabs="https://ptable.com/wiki/compounds/A/Dalteparin_sodium" title="Dalteparin sodium">Dalteparin</a></li>
<li><a href="Enoxaparin_sodium.htm" tppabs="https://ptable.com/wiki/compounds/A/Enoxaparin_sodium" title="Enoxaparin sodium">Enoxaparin</a></li>
<li>Nadroparin</li>
<li>Parnaparin</li>
<li>Reviparin</li>
<li>Tinzaparin</li></ul></li>
<li>Oligosaccharides
<ul><li><a href="Fondaparinux.htm" tppabs="https://ptable.com/wiki/compounds/A/Fondaparinux" title="Fondaparinux">Fondaparinux</a></li>
<li>Idraparinux<sup>§</sup></li></ul></li>
<li>Heparinoids
<ul><li>Danaparoid</li>
<li><a href="Dermatan_sulfate.htm" tppabs="https://ptable.com/wiki/compounds/A/Dermatan_sulfate" title="Dermatan sulfate">Dermatan sulfate</a></li>
<li>Sulodexide</li></ul></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Direct Xa inhibitors ("xabans")</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Apixaban</li>
<li>Betrixaban</li>
<li>Darexaban<sup>§</sup></li>
<li>Edoxaban</li>
<li>Otamixaban<sup>§</sup></li>
<li>Rivaroxaban</li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Direct thrombin (IIa) inhibitors</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Bivalent: Hirudin
<ul><li><a href="Bivalirudin.htm" tppabs="https://ptable.com/wiki/compounds/A/Bivalirudin" title="Bivalirudin">Bivalirudin</a></li>
<li>Desirudin</li>
<li><a href="Lepirudin.htm" tppabs="https://ptable.com/wiki/compounds/A/Lepirudin" title="Lepirudin">Lepirudin</a></li></ul></li>
<li>Univalent: <a href="Argatroban.htm" tppabs="https://ptable.com/wiki/compounds/A/Argatroban" title="Argatroban">Argatroban</a></li>
<li>Dabigatran</li>
<li><span class="new">Efegatran</span></li>
<li>Inogatran<sup>§</sup></li>
<li><a href="Ximelagatran.htm" tppabs="https://ptable.com/wiki/compounds/A/Melagatran" title="Melagatran" class="mw-redirect">Melagatran</a><sup>‡</sup></li>
<li><a href="Ximelagatran.htm" tppabs="https://ptable.com/wiki/compounds/A/Ximelagatran" title="Ximelagatran">Ximelagatran</a><sup>‡</sup></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Other</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Antithrombin III</li>
<li>Defibrotide</li>
<li>Protein C
<ul><li><a href="Drotrecogin_alfa.htm" tppabs="https://ptable.com/wiki/compounds/A/Drotrecogin_alfa" title="Drotrecogin alfa">Drotrecogin alfa</a><sup>‡</sup></li></ul></li>
<li><a href="Ramatroban.htm" tppabs="https://ptable.com/wiki/compounds/A/Ramatroban" title="Ramatroban">Ramatroban</a></li>
<li>REG1</li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Thrombolytic drugs/<br>fibrinolytics</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Plasminogen activators: r-tPA
<ul><li>Alteplase</li>
<li><a href="Reteplase.htm" tppabs="https://ptable.com/wiki/compounds/A/Reteplase" title="Reteplase">Reteplase</a></li>
<li><a href="Tenecteplase.htm" tppabs="https://ptable.com/wiki/compounds/A/Tenecteplase" title="Tenecteplase">Tenecteplase</a></li>
<li>Desmoteplase<sup>†</sup></li></ul></li>
<li>UPA
<ul><li>Saruplase</li>
<li><a href="Urokinase.htm" tppabs="https://ptable.com/wiki/compounds/A/Urokinase" title="Urokinase">Urokinase</a></li></ul></li>
<li><a href="Anistreplase.htm" tppabs="https://ptable.com/wiki/compounds/A/Anistreplase" title="Anistreplase">Anistreplase</a></li>
<li>Monteplase</li>
<li><a href="Streptokinase.htm" tppabs="https://ptable.com/wiki/compounds/A/Streptokinase" title="Streptokinase">Streptokinase</a><sup>#</sup></li>
<li>Other serine endopeptidases: Ancrod</li>
<li>Brinase</li>
<li>Fibrinolysin</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Non-medicinal</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Citrate</li>
<li><a href="Ethylenediaminetetraacetic_acid.htm" tppabs="https://ptable.com/wiki/compounds/A/Ethylenediaminetetraacetic_acid" title="Ethylenediaminetetraacetic acid">EDTA</a></li>
<li><a href="Oxalate.htm" tppabs="https://ptable.com/wiki/compounds/A/Oxalate" title="Oxalate">Oxalate</a></li></ul>
</div></td></tr><tr><td class="navbox-abovebelow" colspan="2" style="background: transparent; padding: 0px;"><div><div class="hlist">
<ul><li><sup>#</sup>WHO-EM</li>
<li><sup>‡</sup>Withdrawn from market</li>
<li>Clinical trials:
<ul><li><sup>†</sup>Phase III</li>
<li><sup>§</sup>Never to phase III</li></ul></li></ul>
</div></div></td></tr></tbody></table></div>



<style data-mw-deduplicate="TemplateStyles:r951705291">.mw-parser-output cite.citation{font-style:inherit}.mw-parser-output .citation q{quotes:"\"""\"""'""'"}.mw-parser-output .id-lock-free a,.mw-parser-output .citation .cs1-lock-free a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/6/65/Lock-green.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/6/65/Lock-green.svg*/);background-repeat:no-repeat;background-size:9px;background-position:right .1em center}.mw-parser-output .id-lock-limited a,.mw-parser-output .id-lock-registration a,.mw-parser-output .citation .cs1-lock-limited a,.mw-parser-output .citation .cs1-lock-registration a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/d/d6/Lock-gray-alt-2.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/d/d6/Lock-gray-alt-2.svg*/);background-repeat:no-repeat;background-size:9px;background-position:right .1em center}.mw-parser-output .id-lock-subscription a,.mw-parser-output .citation .cs1-lock-subscription a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/a/aa/Lock-red-alt-2.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/a/aa/Lock-red-alt-2.svg*/);background-repeat:no-repeat;background-size:9px;background-position:right .1em center}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration{color:#555}.mw-parser-output .cs1-subscription span,.mw-parser-output .cs1-registration span{border-bottom:1px dotted;cursor:help}.mw-parser-output .cs1-ws-icon a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/4/4c/Wikisource-logo.svg/12px-Wikisource-logo.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/4/4c/Wikisource-logo.svg/12px-Wikisource-logo.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/4/4c/Wikisource-logo.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/4/4c/Wikisource-logo.svg*/);background-repeat:no-repeat;background-size:12px;background-position:right .1em center}.mw-parser-output code.cs1-code{color:inherit;background:inherit;border:inherit;padding:inherit}.mw-parser-output .cs1-hidden-error{display:none;font-size:100%}.mw-parser-output .cs1-visible-error{font-size:100%}.mw-parser-output .cs1-maint{display:none;color:#33aa33;margin-left:0.3em}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration,.mw-parser-output .cs1-format{font-size:95%}.mw-parser-output .cs1-kern-left,.mw-parser-output .cs1-kern-wl-left{padding-left:0.2em}.mw-parser-output .cs1-kern-right,.mw-parser-output .cs1-kern-wl-right{padding-right:0.2em}.mw-parser-output .citation .mw-selflink{font-weight:inherit}</style>
    
</details><!--htdig_noindex--><div><div style="clear:both; background-image:linear-gradient(180deg, #E8E8E8, white); border-top: dashed 2px #AAAAAA; padding: 0.5em 0.5em 0.5em 0.5em; margin-top: 1em; direction: ltr;">
    This article is issued from <a class="external text" title="Last edited on 2020-06-19" href="javascript:if(confirm('https://en.wikipedia.org/wiki/?title=Bivalirudin&oldid=963403549  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://en.wikipedia.org/wiki/?title=Bivalirudin&oldid=963403549'" tppabs="https://en.wikipedia.org/wiki/?title=Bivalirudin&oldid=963403549">Wikipedia</a>. The text is licensed under <a class="external text" href="javascript:if(confirm('https://creativecommons.org/licenses/by-sa/4.0/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://creativecommons.org/licenses/by-sa/4.0/'" tppabs="https://creativecommons.org/licenses/by-sa/4.0/">Creative Commons - Attribution - Sharealike</a>. Additional terms may apply for the media files.
</div>
</div><!--/htdig_noindex--></div>
        </div>
      </div>
    </div>
  </div>
  <script src="../-/j/js_modules/jsConfigVars.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/jsConfigVars.js" class=""></script>
  <script src="../-/j/js_modules/startup.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/startup.js" class=""></script>
<script src="../-/j/js_modules/jquery.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/jquery.js" class=""></script>
<script src="../-/j/js_modules/mediawiki.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/mediawiki.js" class=""></script>
<script src="../-/j/js_modules/site.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/site.js" class=""></script>
<script src="../-/j/js_modules/ext.cite.ux-enhancements.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/ext.cite.ux-enhancements.js" class=""></script>



</body></html>